呋塞米(Furosemide) - 药物靶点：NKCC2_在研适应症：慢性肾病，肾病综合征，慢性心力衰竭_专利_临床

概要

基本信息

简介Furosemide是属于NKCC2抑制剂的小分子药物，可阻止肾脏Henle升支中的钠-钾-氯共同转运体的活性。这种机制导致尿液产生增加，钠、氯和钾离子的重吸收减少，从而减少了体液潴留和血压。Furosemide主要被批准用于治疗水肿和高血压，通常还与充血性心力衰竭、肝硬化和肾功能障碍等情况相关。Furosemide于1964年1月首次获批，由跨国制药公司赛诺菲生产。

药物类型

小分子化药

别名

2-Furfurylamino-4-chloro-5-sulfamoylbenzoic acid、4-Chloro-5-sulfamoyl-N-furfuryl-anthranilic acid、4-Chloro-N-(2-furylmethyl)-5-sulfamoylanthranilic acid

+ [23]

靶点

NKCC2

作用方式

抑制剂

作用机制

NKCC2抑制剂(钠钾氯协同转运蛋白-2抑制剂)

治疗领域

神经系统疾病心血管疾病呼吸系统疾病+ [2]

在研适应症

慢性肾病肾病综合征慢性心力衰竭+ [9]

非在研适应症

急性失代偿性心力衰竭终末期肾脏病音量过载

原研机构

Sanofi

在研机构

Fresenius Kabi USA LLC

Nichi-Iko Pharmaceutical Co., Ltd.Sanofi KK

+ [11]

非在研机构

Pharmobedient, Inc.

Sanofi

权益机构

MannKind Corp.

scPharmaceuticals, Inc.

最高研发阶段批准上市

首次获批日期

日本 (1965-05-01),

水肿高血压经前综合征+ [1]

最高研发阶段(中国)批准上市

特殊审评-

登录后查看时间轴

结构/序列

分子式C12H11ClN2O5S

InChIKeyZZUFCTLCJUWOSV-UHFFFAOYSA-N

CAS号54-31-9

关联

349

项与呋塞米相关的临床试验

NCT06941415

/ Not yet recruiting临床3期IIT

Bumetanide vs. Furosemide for Adults Hospitalized With Cirrhosis: the BUFF Trial

Patients with cirrhosis are frequently hospitalized due to an acute decompensation of their liver disease including bleeding, jaundice, encephalopathy, and volume overload. Volume overload is associated with increased mortality from acute hypoxic respiratory failure, hemorrhage from esophageal varices, and spontaneous bacterial peritonitis.
Clinical practice guidelines describe sodium restriction and diuretics as first-line treatment, combined with regular body weight monitoring to assess response. In patients with suboptimal response to furosemide, alternative loop diuretics like torsemide or bumetanide may improve natriuresis. Bumetanide has a theoretic advantage over furosemide due to its more rapid and complete intestinal absorption, combined with a prolonged half-life in patients with hepatic dysfunction. In this pragmatic study, the aim is to compare the efficacy of diuresis with bumetanide versus furosemide among hospitalized patients with cirrhosis.

开始日期2025-10-01

申办/合作机构

University of Utah

NCT07077772

/ Not yet recruitingN/AIIT

Evaluation of Natriuresis-guided Depletion After Cardiac Surgery: a Monocentric, Open-label, Randomized Controlled Trial

Fluid overload (FO) is a common complication after cardiac surgery, associated with increased morbidity and mortality. Loop diuretics, especially furosemide, are routinely used to manage FO, but their use is often empirical. Recent data suggest that natriuresis-guided furosemide titration using point-of-care urinary sodium sensors (LAQUAtwin NA-11, Horiba) may improve the efficiency and safety of fluid removal, but no randomized trial has yet evaluated this approach in postoperative cardiac surgery patients
Our goal is to assess the clinical impact, safety, and feasibility of a natriuresis-guided furosemide protocol after cardiac surgery requiring cardiopulmonary bypass.

开始日期2025-10-01

申办/合作机构

Centre Hospitalier Universitaire Amiens-Picardie

NCT07018297

/ Not yet recruiting临床3期IIT

Early Discharge With Subcutaneous Furosemide Versus Standard Care in Acute Heart Failure: A Cluster-Randomized Crossover Non-Inferiority Trial

This will be a prospective, cluster-randomized, crossover, non-inferiority trial of 250 participants within 48 hours of an inpatient admission for heart failure or emergency department presentation for heart failure with plans for admission or observation/short-stay hospitalization comparing early discharge using subcutaneous furosemide to standard inpatient care. Individual practice groups will serve as "clusters" and the unit of randomization. Each participating cluster will implement either the early discharge strategy using the intervention or standard care for initial two-month blocks, followed by a crossover to the alternate strategy. The primary outcome is days alive and out of hospital at 30 days.

开始日期2025-09-15

申办/合作机构

The University of Texas Southwestern Medical Center

100 项与呋塞米相关的临床结果

登录后查看更多信息

100 项与呋塞米相关的转化医学

登录后查看更多信息

100 项与呋塞米相关的专利（医药）

登录后查看更多信息

19,672

项与呋塞米相关的文献（医药）

2025-12-31·RENAL FAILURE

It is not only fluids: the impact of hydration protocols used for the prevention of contrast nephropathy on renal oxygenation

Review

作者: Heyman, Samuel N. ; Abassi, Zaid ; Solomon, Richard

Fluid administration is the mainstay intervention effective in the prevention of radiocontrast-associated nephropathy (CAN) in high-risk patients. Vigorous hydration shortens intratubular solute transit-time and reduces tubular intraluminal concentration of contrast media (CM), decreasing exposure of tubular cells to CM and reducing renal parenchymal retention of the nephrotoxin. Lowered plasma and urine viscosity might also improve vasa recta flow and renal interstitial pressure, improving compromised renal parenchymal microcirculation and oxygenation. Herein we emphasize the overlooked plausible role of down-regulation of tubular transport, generated by vigorous hydration in the mitigation of medullary hypoxia and hypoxic medullary damage generated in CAN. Volume expansion triggers natriuretic peptides that improve renal parenchymal oxygenation and may attenuate hypoxic renal injury. Furthermore, enhanced large-volume hydration protocols used for high-risk patients undergoing coronary interventions or transcatheter aortic valve implantation include the administration of furosemide. Loop diuretics block oxygen consumption in medullary thick ascending limbs, improve medullary oxygenation and prevent outer medullary injury in experimental CAN. Thus, fluids are likely not the sole issue, and restoration of medullary oxygenation is critical in attenuating the risk of CAN by large volume hydration protocols for high-risk patients.

2025-12-01·JOURNAL OF CRITICAL CARE

Response to furosemide and the receipt of kidney replacement therapy in critically ill patients

Article

作者: Angel, Yoel ; Khoury, Nardeen ; Dayan, Roy Rafael ; Wald, Ron ; Stavi, Dekel ; Adi, Nimrod ; Goder, Noam ; Sold, Oded ; Lichter, Yael ; Gal Oz, Amir

BACKGROUND:

The administration of furosemide can predict the likelihood of clinical deterioration in patients with early-stage acute kidney injury (AKI). This study aimed to evaluate the response to a patient's first furosemide bolus administered during ICU admission in critically ill patients, and to assess the significance of this response in predicting the need for kidney replacement therapy (KRT).

METHODS:

This retrospective cohort study included critically ill adult patients admitted to a tertiary care hospital ICU between 2017 and 2023 who received a first intravenous furosemide bolus with documented urine output. Patients treated with continuous furosemide infusion were excluded. The response to furosemide was assessed at 2 and 6 h after administration. The primary outcome was the initiation of kidney replacement therapy (KRT) within 7 days.

RESULTS:

A total of 1527 critically ill patients were included in the analysis. Among patients with urine output ≤25 mL/h during the first 2 h post-furosemide, 23.9 % received KRT within 7 days, compared to 8.8 % in the 25.1-50 mL/h group and 3.6 % in the >50 mL/h group (p < 0.001). Similar patterns were observed for urine output at 6 h. Lower urine output was also associated with greater AKI progression and higher KDIGO stages. In multivariable analysis, lower urine output at 6 h remained a significant predictor of KRT initiation (adjusted OR per 10 mL/h increase: 0.905, 95 % CI: 0.861-0.951).

CONCLUSIONS:

This study demonstrates that the response to a first furosemide bolus administered during usual clinical care can be a valuable tool for anticipating the future receipt of KRT.

2025-11-01·Current Drug Safety

Diuretics-Induced Acute Pancreatitis: Case Series with a Review of the Literature

Review

作者: Patel, Dhruvkumar M. ; Patel, Lalitkumar B. ; Patel, Vahin B ; Patel, Mukundkumar V. ; Patel, Dhara K. ; Patel, Maitri M.

Background::

Although diuretic-induced Acute Pancreatitis (AP) cases are typically mild to moderate, severe and potentially fatal occurrences can arise.

Case Series and Literature Review::

We have, herein, presented a series of diuretic-induced AP cases from March 2018 to February 2024 of a 54-year-old woman treated with chlorthalidone, a 45-year-old male treated with hydrochlorothiazide, and a 48-year-old male treated with frusemide. The literature search has identified 26 cases published to date, 10 from frusemide and 16 from thiazide diuretics. The Naranjo adverse reaction probability scale has categorized all three drugs as “probable”. All cases have responded to conservative treatment and cessation of the offending drug. Various mechanisms, such as hypersensitization, ischemia, direct cytotoxic effects, hypercalcemia, and dose-dependent idiosyncrasy, have been found to lead to intrapancreatic activation of pancreatic enzymes, resulting in drug-induced AP.

Conclusion::

Further research into the mechanisms and genetic factors contributing to diureticinduced AP is essential for enabling early diagnosis and management of diuretic-induced AP.

316

项与呋塞米相关的新闻（医药）

2025-08-25

·FiercePharma

MannKind grabs scPharmaceuticals and its heart failure infuser Furoscix in $360M deal

The deal is expected to close by the fourth quarter of 2025. With a buyout of scPharmaceuticals worth up to $360 million, MannKind is looking to dive into the large and growing field of cardiometabolic treatments.Endocrine and orphan lung disease-focused MannKind will shell out $5.35 per share—plus a contingent value right (CVR) of $1.00 per share—to buy scPharmaceuticals and Furoscix, the latter company's on-body infuser that delivers furosemide.The total deal value of $360 million represents a 31% premium to scPharmaceuticals’ Aug. 22 closing price, according to a Monday press release.With the deal, MannKind will add scPharmaceuticals’ Furoscix to its lineup of marketed products. The 2022-approved drug is an on-body infuser that delivers generic furosemide as a self-administered, subcutaneous loop diuretic to help relieve the fluid retention and swelling that accompany heart failure and other conditions.In March, Furoscix tacked on a new indication, allowing its use to treat edema in patients with chronic kidney disease (CKD).Over the first half of this year, scPharmaceuticals pulled in sales growth of 96% from the same period last year, generating $27.8 million. MannKind expects its own established strengths in the endocrinology department to help boost Furoscix’s market opportunity in CKD, and it plans to continue utilizing the “talented team” at scPharmaceuticals to continue fostering the drug's growth.MannKind currently markets inhalation powder Afrezza for type 1 and 2 diabetes, plus an all-in-one insulin delivery patch V-Go as well as United Therapeutics-partnered pulmonary arterial hypertension (PAH) treatment Tyvaso DPI. With Furoscix in the mix, the company expects its annual sales will grow beyond $370 million.The company amended a strategic financing agreement with Blackstone to add $175 million in additional funding to support the acquisition. ScPharmaceuticals’ shares surged more than 14.90% on Monday morning to $5.58, while MannKind’s dipped by 5.35% to $3.89.

并购上市批准

2025-08-25

·Medaverse

3.6亿美元！MannKind收购scPharmaceuticals

8月25日，MannKind（Nasdaq:MNKD）和scPharmaceuticals（Nasdaq:SCPH）宣布签署最终合并协议，由MannKind收购scPharmaceuticals。MannKind将立即开始要约收购scPharmaceuticals普通股的所有已发行股份，收盘时以每股5.35美元的现金价格加上每股不可交易的CVR，以获得每股CVR总计1.00美元的里程碑付款，现金总对价高达每股6.35美元，收盘时股权总价值约为3.03亿美元，交易总价值高达约3.6亿美元。此次拟议的收购标志着MannKind向心肾医学领域的战略扩张，与孤儿肺业务部门一起建立了公司的心脏代谢业务。sc Pharmaceuticals目前销售FUROSCIX，这是一种经美国FDA批准的体内输液器，可递送呋塞米，是治疗慢性心力衰竭（CHF）和慢性肾病（CKD）成年患者液体超负荷的金标准。据估计，仅在美国潜在市场机会总额就超过100亿美元。 scPharmaceuticals凭借其2024年的销售队伍扩张、对肾脏病学的持续推出以及综合交付网络的加速增长，展现出强劲的商业势头。截至2025年6月30日的六个月，净销售额总计2780万美元，同比增长96%。FUROSCIX ReadyFlow自动注射器有望在2025年第三季度提交补充新药申请（sNDA），有可能使患者将治疗时间从5小时缩短到不到10秒。 MannKind Corporation首席执行官Michael Castagna表示：“此次收购扩大了我们以患者为中心的品牌，突显了MannKind致力于为心脏代谢和孤儿肺病提供创新疗法。随着多个预期的产品发布和指标扩张，我们预计将继续使我们的收入来源多样化，并在未来十年加快实现两位数的增长目标。” scPharmaceuticals首席执行官John Tucker表示：“与MannKind的这笔交易代表着scPharmaceedicals和FUROSCIX品牌令人兴奋的下一章。通过将我们的创新产品与MannKind经过验证的商业能力相结合，并共同致力于推进患者护理，我们相信MannKind可以加速获得重要疗法，并为患者、提供者和股东创造有意义的价值。” 战略和财务效益使MannKind的收入基础和增长多样化。合并后的公司预计将拥有更强大的收入基础，在Afrezza®、FUROSCIX和V-Go®拥有三项商业化资产。根据2025年第二季度的业绩，这些互补的商业产品与Tyvaso DPI®相关收入相结合，年化运行率超过3.7亿美元。MannKind预计其商业产品将产生两位数的年增长率，并有潜在的加速器来扩大其在美国和全球的市场范围： Afrezza成人标签更新，印度推出，儿科提交补充生物制品许可证申请 FUROSCIX自动注射器有望在2025年第三季度提交sNDA 特发性肺纤维化（IPF）中Tyvaso的TETON 1和2研究即将发表的读数与现有MannKind基础设施的战略契合有望释放有意义的增长机会。两家公司拥有互补的商业模式和文化，致力于为那些有重大未满足医疗需求的人提供方便、以患者为中心的治疗。scPharmaceuticals拥有深厚的心血管专业知识，而MannKind在内分泌学方面的优势使其能够有效地支持最近的CKD批准。通过利用其现有的商业基础设施和团队与肾病学家合作，MannKind有能力加快FUROSCIX在CKD的市场机会。MannKind希望通过scPharmaceuticals已经建立的才华横溢的团队，继续FUROSCIX在CHF的持续成功。长期价值驱动因素继续发展。除了已上市的产品外，MannKind还在推进一项后期产品线，其中包括吸入Clofazimine（氯法齐明MNKD-101）和尼达尼布DPI（MNKD-201），吸入氯法齐明目前正处于非结核分枝杆菌（NTM）肺病的3期全球研究中，尼达尼布DPI预计将在2025年底前启动IPF的2期临床试验。 MannKind拥有充足的资本来支持其战略目标。MannKind和Blackstone修改了他们最近宣布的战略融资协议，提供1.75亿美元的额外资金来支持此次收购。关注下方公众号，带你看世界!

并购孤儿药

2025-08-25

·EndPoints

MannKind to buy scPharmaceuticals for up to $360M; Arnatar launches with $52M

Plus, news about Vaxxas, Mid-Atlantic BioTherapeutics, Incyclix Bio and Invivyd: 🫀 MannKind to buy scPharmaceuticals: The Connecticut biopharma is paying $5.35 per share upfront in cash, plus a potential milestone payment of up to $1.00 per share. The deal gives scPharmaceuticals an equity value of $303 million upfront or $360 million total if the CVR is achieved. The FDA in 2022 approved scPharmaceuticals’ drug-device product Furoscix for certain types of heart failure. MannKind said it would have to pay about $81 million to get out of a credit facility that scPharmaceuticals had inked with Perceptive Advisors . Blackstone is helping fund the acquisition as part of an amendment to a financing agreement earlier this month. MannKind’s stock $SCPH was down about 5% on Monday morning. — Kyle LaHucik 🔬There’s a new RNA medicines biotech: Arnatar Therapeutics, a San Diego biotech founded by former Ionis leaders, launched Monday with a pipeline of RNA medicines for cardio metabolic, liver, kidney and CNS diseases. The company unveiled a $52 million Series A, though it said the round closed last year. Its candidates include Phase 1-stage ART101 for hypertension and ART4, an antisense oligonucleotide for Alagille syndrome that’s been granted orphan and rare pediatric disease designations. — Kyle LaHucik 🩹 Vaxxas raises about $58M for its needle-free vaccine tech: The biotech secured about 90 million Australian dollars to boost production of its high-density microarray patch for “market readiness.” The needle-free vaccine technology has so far been administered to over 750 participants in clinical trials and has shown robust immune response, according to Vaxxas. The funding marks one of this year’s largest financings for a private biotech in Australia. — Alexis Kramer 💰 Mid-Atlantic BioTherapeutics to get up to $50M: Legend Innovation Life Science Fund said Saturday that its planned investment will support Mid-Atlantic’s development of new “anti-aging” drugs for neurological diseases and cancer. Mid-Atlantic should expect the first funding tranche in the third quarter of this year before it begins a Phase 3 trial for its viral encephalitis drug in 2026. — Alexis Kramer 💸 Incyclix Bio extends Series B with $11.3M: The company is working on a CDK2 inhibitor that’s headed to a Phase 1/2 trial, with the help of the new funding. The extension’s investors include Eshelman Ventures, Eli Lilly, Pharmacosmos and Cape Fear BioCapital. — Jaimy Lee 🏷️ Invivyd ended up raising $57.5 million in its public offering, up from the $50 million it sought. — Jaimy Lee

疫苗上市批准并购临床3期

100 项与呋塞米相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00331	呋塞米	C03CA01	DB00695

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
慢性肾病	美国	scPharmaceuticals, Inc.	2025-03-06
肾病综合征	美国	scPharmaceuticals, Inc.	2025-03-06
慢性心力衰竭	美国	scPharmaceuticals, Inc.	2022-10-07
心源性水肿	日本	Nichi-Iko Pharmaceutical Co., Ltd.	2002-10-31
心脏衰竭	日本	Nichi-Iko Pharmaceutical Co., Ltd.	2002-10-31
急性肺水肿	澳大利亚	Sanofi-Aventis Australia Pty Ltd.	1991-08-01
脑水肿	澳大利亚	Sanofi-Aventis Australia Pty Ltd.	1991-08-01
少尿	日本	Sanofi KK	1981-09-01
水肿	日本	Sanofi KK	1965-05-01
高血压	日本	Sanofi KK	1965-05-01
经前综合征	日本	Sanofi KK	1965-05-01
泌尿结石	日本	Sanofi KK	1965-05-01

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
急性失代偿性心力衰竭	临床3期	美国	scPharmaceuticals, Inc.	2016-02-01
音量过载	临床2期	荷兰	scPharmaceuticals, Inc.	2014-12-01
终末期肾脏病	临床1期	加拿大	Sanofi	2012-11-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05528588 (RESISTANCE-HF, CTgov)	临床2期	心脏衰竭 \| 急性失代偿性心力衰竭	70	Furoscix (? 12 BAN-ADHF, Furoscix)	繭繭鑰餘築簾選廠簾網(醖獵鹹艱顧壓築淵觸網) = 餘顧襯膚願願觸糧齋觸網構壓衊膚壓構窪衊鹹 (鏇膚遞製築鹽夢鹹築衊, 衊窪鏇製製窪選蓋膚襯 ~ 衊夢憲艱廠遞鏇構衊窪) 更多	-	2025-07-16
				Furoscix (<= 11 BAN-ADHF, Furoscix)	繭繭鑰餘築簾選廠簾網(醖獵鹹艱顧壓築淵觸網) = 衊築積獵製製觸顧簾顧網構壓衊膚壓構窪衊鹹 (鏇膚遞製築鹽夢鹹築衊, 衊糧鹹遞鏇醖醖製淵鬱 ~ 鬱簾鹹糧選壓醖艱鹽鑰) 更多
NCT04216784 (CTgov)	临床4期	代谢性疾病	21	Furosemide Injection (Furosemide (Lasix) Alone)	壓網窪夢製壓壓鑰鏇選(夢遞遞艱鬱簾鹹築膚獵) = 鹽鹽選糧齋積淵製餘構願憲構選糧衊衊艱範選 (網鹹築觸鹽繭蓋簾鹹範, 鏇壓選淵壓鬱顧觸廠獵 ~ 衊顧餘齋糧襯選糧鏇膚) 更多	-	2025-05-09
				Albumin Human+Furosemide Injection (Combination of Furosemide (Lasix) and Albumin)	壓網窪夢製壓壓鑰鏇選(夢遞遞艱鬱簾鹹築膚獵) = 壓鏇網艱餘選繭膚餘膚願憲構選糧衊衊艱範選 (網鹹築觸鹽繭蓋簾鹹範, 願膚製餘齋艱壓憲築鬱 ~ 鏇夢顧窪鏇製遞獵積淵) 更多
NCT05093621 (TFO, CTgov)	临床3期	心脏衰竭	47	furosemide (Furosemide)	鹹鹹衊鬱積範鬱簾襯顧 = 顧衊鑰淵顧簾築艱構築顧遞獵範築選夢觸淵鹽 (鏇鑰鬱顧選選艱鑰範窪, 構襯窪鬱願網鏇糧顧築 ~ 鑰夢憲鹽構鹹糧鬱簾襯) 更多	-	2024-10-15
				Torsemide (Torsemide)	鹹鹹衊鬱積範鬱簾襯顧 = 鑰築鑰獵鹽衊鹽簾窪醖顧遞獵範築選夢觸淵鹽 (鏇鑰鬱顧選選艱鑰範窪, 艱選窪顧餘衊願構簾襯 ~ 鬱蓋蓋窪鑰蓋簾簾齋鹽) 更多
NCT00690521 (CTgov)	N/A	心脏衰竭 \| 慢性充血性心力衰竭	8	Arm1+Hydrochlorothiazide+Metolazone+Furosemide (Arm1- Furosemide and Hydrochlorothiazide Then Furosemide + Metolazone)	衊鑰製醖範鹽壓觸衊鹽 = 簾範範醖廠糧壓網衊蓋繭鹹夢鬱壓構築蓋壓選 (醖蓋鬱鹹糧顧繭構醖願, 鹽衊鹹糧製夢襯願壓廠 ~ 淵鬱夢繭膚糧築獵繭構) 更多	-	2024-10-10
				Arm2+Hydrochlorothiazide+Metolazone+Furosemide (Arm2-Furosemide and Metolazone Then Furosemide and Hydrochlorothiazide)	衊鑰製醖範鹽壓觸衊鹽 = 獵膚夢鑰鏇壓範壓鹹範繭鹹夢鬱壓構築蓋壓選 (醖蓋鬱鹹糧顧繭構醖願, 鬱醖繭艱繭艱夢願觸廠 ~ 餘觸願鏇鬱淵淵糧廠鑰) 更多
NCT06167707 (GlobeNewswire) 人工标引	临床1期	-	-	SCP-111 Autoinjector	簾選鏇鹽膚製壓廠遞窪(範憲積網憲鑰積選艱衊) = 廠鬱觸獵顧壓膚蓋壓築繭鹽衊鏇夢憲夢製願選 (夢製範夢蓋鏇鬱觸鹽餘, 103.9 ~ 110.8) 更多	积极	2024-08-12
NCT03296813 (TRANSFORM-HF, Pubmed \| Eur J Heart Fail) 人工标引	临床3期	心脏衰竭	2,570	Torsemide	鏇窪網繭簾糧選築鑰鏇(觸襯鬱簾遞醖製廠簾餘) = 衊製製範鏇蓋鏇憲淵憲鹽蓋鏇艱膚膚壓簾築鬱 (獵鏇膚衊簾窪膚網壓齋 ) 更多	不佳	2024-05-15
				Furosemide	鏇窪網繭簾糧選築鑰鏇(觸襯鬱簾遞醖製廠簾餘) = 願繭遞積鹹觸醖簾繭願鹽蓋鏇艱膚膚壓簾築鬱 (獵鏇膚衊簾窪膚網壓齋 ) 更多
AUA2024	N/A	肾积水	-	LASIX (Progression)	壓構鹹顧製鬱鹽獵醖淵(衊製膚觸淵選淵觸衊範) = 願膚膚膚築鹹醖窪鹽簾醖簾獵製艱鏇襯齋艱廠 (築夢憲構憲醖鑰夢範壓 ) 更多	-	2024-05-01
				LASIX (Stable/Improved)	鑰憲鹽膚選鹽顧衊廠膚(遞製簾願艱製積憲觸蓋) = 鬱醖夢選鹽製繭醖積選鹽鬱範築壓簾選選壓願 (鏇積鏇糧淵衊鹹廠膚窪, -67% ~ -6.0%)
NCT04615624 (CTgov)	临床3期	先兆子痫	65	furosemide (Furosemide)	蓋醖鹹窪鬱鏇膚網廠構(顧網範壓蓋築選鹽鹽糧) = 壓淵窪鬱壓齋繭憲願壓蓋壓鏇鬱艱餘顧醖鏇鑰 (鑰鹹廠簾壓鹹衊簾簾艱, 14.8) 更多	-	2024-04-18
				Placebo (Placebo)	蓋醖鹹窪鬱鏇膚網廠構(顧網範壓蓋築選鹽鹽糧) = 醖鬱醖夢構壓製糧襯觸蓋壓鏇鬱艱餘顧醖鏇鑰 (鑰鹹廠簾壓鹹衊簾簾艱, 13.8) 更多
NCT04615624 (Pubmed \| Am J Obstet Gynecol MFM)	临床3期	高血压，严重一线	65	Intravenous Furosemide	蓋鹽積窪簾築餘積衊餘(築夢顧獵膚蓋鏇壓鏇製) = greater in the furosemide group 網獵鑰壓範衊繭範選廠 (襯夢襯鑰選衊遞顧積積 )	积极	2024-04-01
				Placebo
NCT04982874 (CTgov)	N/A	-	24	Furosemide 40 mg (Furosemide 40 mg Tablet)	廠積簾壓鑰膚鑰憲襯襯(膚艱餘觸鏇願夢醖艱艱) = 齋選鹹蓋壓壓鬱廠窪積糧壓鬱餘窪製醖獵膚醖 (鏇製蓋膚觸膚鬱膚鬱廠, 衊鏇製選鏇顧積獵觸網 ~ 蓋築壓願獵鏇觸衊鏇鏇) 更多	-	2023-11-02
				Lasix® 40 mg Tablet (Lasix® 40 mg Tablet)	糧積選糧廠蓋築構範膚(淵夢鬱製窪鑰淵夢鬱壓) = 窪夢憲網醖鹽選齋積鑰繭鏇糧鬱網築築鬱餘齋 (壓鹹願選遞簾醖顧願願, 707.72) 更多